Sawai Group Holdings Co., Ltd. Stock

Equities

4887

JP3323040000

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-05-01 am EDT 5-day change 1st Jan Change
5,826 JPY -0.95% Intraday chart for Sawai Group Holdings Co., Ltd. -5.99% +11.84%
Sales 2024 * 194B 1.23B Sales 2025 * 203B 1.29B Capitalization 258B 1.63B
Net income 2024 * 19.79B 125M Net income 2025 * 19.91B 126M EV / Sales 2024 * 1.51 x
Net Debt 2024 * 34.69B 220M Net Debt 2025 * 39.72B 252M EV / Sales 2025 * 1.46 x
P/E ratio 2024 *
13.1 x
P/E ratio 2025 *
12.9 x
Employees 3,393
Yield 2024 *
2.21%
Yield 2025 *
2.34%
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Sawai Group Finalizes Sale of US Subsidiary MT
Bora Pharmaceuticals Co., LTD. completed the acquisition of Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd.. CI
Jefferies Adjusts Sawai Group’s Price Target to 5,000 Yen From 5,200 Yen, Keeps at Hold MT
Sawai Group Holdings Co., Ltd. Provides Year End Dividend Guidance for the Year Ending March 31, 2024 CI
Sawai Group Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 CI
Bora Pharmaceuticals Co., LTD. agreed to acquire Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. for approximately $210 million. CI
Neurolief Ltd. announced that it has received funding from Sawai Group Holdings Co., Ltd. CI
Jefferies Adjusts Sawai’s Price Target to 4,500 Yen From 3,500 Yen, Keeps at Hold MT
Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 CI
Sawai Group Holdings Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024 CI
Sawai Group Holdings Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year Ending March 31, 2024 CI
Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for Period Ending September 2023 and Year Ending March 2024 CI
Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half Year Ending September 2023 and Fiscal Year Ending March 31, 2024 CI
Sawai Group Holdings Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023; Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024 CI
Sawai Group Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
More news
1 day-0.85%
1 week-5.89%
Current month-3.28%
1 month-0.07%
3 months+4.76%
6 months+26.02%
Current year+11.96%
More quotes
1 week
5 716.00
Extreme 5716
6 315.00
1 month
5 579.00
Extreme 5579
6 315.00
Current year
5 104.00
Extreme 5104
6 498.00
1 year
3 255.00
Extreme 3255
6 498.00
3 years
3 255.00
Extreme 3255
6 498.00
5 years
3 255.00
Extreme 3255
7 430.00
10 years
3 255.00
Extreme 3255
8 560.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 67 21-03-31
President 66 21-03-31
Director/Board Member 64 21-03-31
Members of the board TitleAgeSince
Chief Executive Officer 67 21-03-31
Director/Board Member 56 21-03-31
Director/Board Member 73 21-03-31
More insiders
Date Price Change Volume
24-05-01 5,826 -0.95% 222 000
24-04-30 5,882 -1.26% 194,900
24-04-26 5,957 +0.17% 147,300
24-04-25 5,947 -2.89% 140,000
24-04-24 6,124 -1.18% 291,000

Delayed Quote Japan Exchange, May 01, 2024 at 01:48 am EDT

More quotes
Sawai Group Holdings Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of medical and over-the-counter drugs. The Company operates in two segments. The Japan segment is engaged in medical and healthcare-related businesses such as manufacture and sale of pharmaceuticals and medical devices, as well as various related businesses. The America segment is engaged in the sale of manufactured pharmaceutical products to wholesale stores in America. The company is also engaged in the research and development of pharmaceutical products.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
5,882 JPY
Average target price
6,780 JPY
Spread / Average Target
+15.27%
Consensus